Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HTR1E | P28566 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707552 | 0.95 | KMT2A (0.58) | KMT2AMEN1POLBMAPTNPC1 | |
| SCHEMBL6203117 | 0.87 | MAPT (0.69) | KMT2AMEN1POLBMAPTNPC1 | |
| SCHEMBL7229213 | 0.85 | MAPT (0.63) | KMT2AMEN1POLBMAPTNPC1 | |
| SCHEMBL343011 | 0.81 | MAPT (0.77) | KMT2AMEN1POLBMAPTNPC1 | |
| SCHEMBL7229777 | 0.81 | MAPT (0.64) | KMT2AMEN1POLBMAPTNPC1 | |
| SCHEMBL6222897 | 0.79 | KMT2A (0.82) | KMT2AMEN1POLBMAPTNPC1 | |
| SCHEMBL11632540 | 0.78 | MEN1 (0.49) | KMT2AMEN1POLBMAPTNPC1 | |
| SCHEMBL27972914 | 0.77 | NPSR1 (0.74) | KMT2AMEN1POLBMAPTNPC1 | |
| SCHEMBL6708325 | 0.77 | L3MBTL1 (0.59) | KMT2AMEN1POLBALDH1A1CYP3A4 | |
| SCHEMBL7877273 | 0.76 | NPSR1 (0.77) | KMT2AMEN1POLBMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2004-06-03 | — | — | US | disclosed |
| EP-0727998-B1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| EP-1306377-A2 | Pyridyl-oxazoles and their use as cytokines inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-6333414-B1 | BY REACTION OF THIOUREA WITH THE CORRESPONDING DIKETONE ESTER; CARRIED OUT UNDER REACTION CONDITIONS, PARTICULARLY WITH RESPECT TO PH, WHICH ARE INDUSTRIALLY MORE FAVORABLE. | L'ORéAL S.A. (FR) | 2001-12-25 | — | — | US | disclosed |
| US-6288062-B1 | INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-11 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5686455-A | Imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0727998-A4 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0727998-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013067-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-18 | — | — | WO | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | IL2, IL17A, IL5 | KMT2A 4725/4885MEN1 2711/4885POLB 4219/4885 |
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | KMT2A 2124/4885MEN1 3003/4885POLB 1298/4885 |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | IL17A, IL4I1, IL2 | KMT2A 4818/4885MEN1 2842/4885POLB 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.